Manages medical equipment logistics and reprocessing for healthcare facilities. Now — the numbers.
Revenue is spread across several lines; no single product carries the company.
The company closed last year at a loss: costs ran above sales. The picture changes only if spending is reined in.
Average growth of 18% a year over the last 4 years. Red columns mark years that ended in a loss.
Before the clock runs out, either sales must climb sharply or new money must come in. This is the most critical line in the whole picture.
This company is not turning a profit, so the market is pricing its sales instead: 1.2× for every dollar of annual revenue.
Analysts' average target sits 99% above today's price.
An investor who bought at the very peak is down 61% today. The business is the same; what changed most is the price — and the expectations — the market pins on it.
Over the last 4 years, sales grew about 18% a year on average.
The company sells $1.2B a year; the problem isn’t sales — it’s costs running above that number.
A loss of $19.4M against $1.2B in annual sales.
At the current pace of spending, the cash lasts about 1 year. After that, the company needs to find new money.
Over the last 12 months, executives reported 127 sells against just 25 buys. Not an alarm bell by itself, but a number worth watching.
We don’t have a report card for this stock yet — the data isn’t mature enough to grade. No grade is information too: it means the evidence is thin.
One-line summary: few numbers, an untested story. Keep watching.